Shuttle Pharmaceuticals Holdings, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) on September 8, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC. It is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on corporate governance changes rather than financial performance.
Material Changes
On September 8, 2025, the Board of Directors appointed Adam Chambers as a new director. Mr. Chambers is the principal of Bowery Consulting Group Inc., which serves as the lender under the Company's revolving loan agreement dated February 28, 2025. Additionally, the Company and Bowery Consulting Group Inc. entered into a consulting services agreement on March 21, 2025.
Guidance, Outlook, and Risks
The filing does not contain guidance, outlook, or management commentary regarding future financial performance. A material relationship exists between the new director and a company lender/consultant, which is disclosed as a potential conflict of interest context, though no other direct material interests were identified.
Investor Verification Checklist
- Verify the terms of the revolving loan agreement with Bowery Consulting Group Inc. dated February 28, 2025.
- Review the consulting services agreement dated March 21, 2025, between the Company and Bowery Consulting Group Inc.
- Confirm the independence status of the new director, Adam Chambers, given his role as a lender principal.
- Check for any subsequent filings regarding the Company's liquidity status given the reliance on the revolving loan.